Psoriasis News

The VISIBLE trial demonstrated that intentional efforts to recruit and retain patients with skin of color result in a speedy enrollment process and diverse patient pool, according to a study.

Skin inflammation, such as psoriasis, was associated with systemic inflammation, whereas both psoriasis severity and systemic inflammation were linked with cardiovascular disease, according to a study.

The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.

As the year comes to a close, Healio Dermatology has assembled this year’s top psoriasis articles. 

Veterans continue to experience worse health outcomes than the general population.

Johnson & Johnson has submitted two supplemental biologics license applications to the FDA for Tremfya for the treatment of plaque psoriasis and juvenile psoriatic arthritis in children, the company announced in a press release.

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

Patients with moderate to severe psoriasis experienced higher rates of skin clearance through 1 year with oral JNJ-77242113 treatment compared with placebo, according to phase 2 study results.